Re-treatment with three drugs for stubborn triple negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 70 years.
- Your breast cancer must be 'triple negative' (no estrogen, progesterone, or HER2 receptors).
- Your cancer must have spread or come back, and must have gotten worse after you received immunotherapy before.
- You must have at least one tumor that can be measured on a scan, and your overall health should be fairly good (able to do light activities).
- You must not have had radiation or major surgery in the past 3 weeks, and you must not have untreated or active brain metastases.
- You must be willing to use birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This study tests a combination of three drugs—lenvatinib (a targeted therapy that blocks blood vessel growth), sintilimab (an immunotherapy that helps your immune system attack cancer), and nab-paclitaxel (a chemotherapy)—as the first treatment for triple negative breast cancer that has spread. The goal is to see if this combination is safe and effective.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.